Literature DB >> 10371505

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.

T Sethi1, R C Rintoul, S M Moore, A C MacKinnon, D Salter, C Choo, E R Chilvers, I Dransfield, S C Donnelly, R Strieter, C Haslett.   

Abstract

Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of beta1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a specialized microenvironment, and the survival of cells bound to ECM could explain the partial responses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based on blocking beta1 integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371505     DOI: 10.1038/9511

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  226 in total

Review 1.  Integrins in invasive growth.

Authors:  Cord Brakebusch; Daniel Bouvard; Fabio Stanchi; Takao Sakai; Reinhard Fässler
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 2.  Integrin signalling and the cellular response to ionizing radiation.

Authors:  Nils Cordes; Viktor Meineke
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

3.  Gene expression analysis to identify molecular correlates of pre- and post-conditioning derived neuroprotection.

Authors:  Shiv S Prasad; Marsha Russell; Margeryta Nowakowska; Andrew Williams; Carole Yauk
Journal:  J Mol Neurosci       Date:  2012-04-01       Impact factor: 3.444

Review 4.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

5.  Fibroblasts contribute to melanoma tumor growth and drug resistance.

Authors:  Edward H Flach; Vito W Rebecca; Meenhard Herlyn; Keiran S M Smalley; Alexander R A Anderson
Journal:  Mol Pharm       Date:  2011-11-08       Impact factor: 4.939

6.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

7.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

Review 8.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

Review 9.  Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.

Authors:  Matthew David Hale; Jeremy David Hayden; Heike Irmgard Grabsch
Journal:  Cell Oncol (Dordr)       Date:  2013-03-14       Impact factor: 6.730

10.  alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer.

Authors:  Jesse Roman; Jeffrey D Ritzenthaler; Sussane Roser-Page; XiaoJuan Sun; ShouWei Han
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.